Canadian Consensus for Treatment of BRAF V600E Mutated Pediatric and AYA Gliomas
Abstract
:1. Introduction
2. Methods
3. Results
- Timepoint 0 months—BRAFi 100%; MEKi 100%
- Timepoint 3 months—BRAFi 100%; MEKi 75%
- Timepoint 6 months—BRAFi 75%; MEKi 50%
- Timepoint 9 months—BRAFi 75%; MEKi 25%
- Timepoint 12 months—BRAFi 50%; MEKi 0
- Timepoint 15 months—BRAFi 50%; MEKi 0
- Timepoint 18 months—BRAFi 25%; MEKi 0
- Timepoint 21 months—BRAFi 25%; MEKi 0
- Timepoint 24 months—BRAFi 0; MEKi 0
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Conflicts of Interest
References
- Sievert, A.J.; Fisher, M.J. Pediatric low-grade gliomas. J. Child. Neurol. 2009, 24, 1397–1408. [Google Scholar] [CrossRef]
- Fisher, P.G.; Tihan, T.; Goldthwaite, P.T.; Wharam, M.D.; Carson, B.S.; Weingart, J.D.; Repka, M.X.; Cohen, K.J.; Burger, P.C. Outcome analysis of childhood low-grade astrocytomas. Pediatr. Blood Cancer 2008, 51, 245–250. [Google Scholar] [CrossRef] [PubMed]
- Ater, J.L.; Zhou, T.; Holmes, E.; Mazewski, C.M.; Booth, T.N.; Freyer, D.R.; Lazarus, K.H.; Packer, R.J.; Prados, M.; Sposto, R.; et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: A report from the Children’s Oncology Group. J. Clin. Oncol. 2012, 30, 2641–2647. [Google Scholar] [CrossRef] [PubMed]
- Lassaletta, A.; Scheinemann, K.; Zelcer, S.M.; Hukin, J.; Wilson, B.A.; Jabado, N.; Carret, A.S.; Lafay-Cousin, L.; Larouche, V.; Hawkins, C.E.; et al. Phase II Weekly Vinblastine for Chemotherapy-Naive Children with Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study. J. Clin. Oncol. 2016, 34, 3537–3543. [Google Scholar] [CrossRef]
- Ostrom, Q.T.; Price, M.; Neff, C.; Cioffi, G.; A Waite, K.; Kruchko, C.; Barnholtz-Sloan, J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015–2019. Neuro Oncol. 2022, 24 (Suppl. S5), v1–v95. [Google Scholar] [CrossRef]
- Bennett, J.; Bouffet, E. Neuro-oncology in adolescents and young adults-an unmet need. Neuro Oncol. 2020, 22, 752–753. [Google Scholar] [CrossRef] [PubMed]
- Jones, D.T.; Gronych, J.; Lichter, P.; Witt, O.; Pfister, S.M. MAPK pathway activation in pilocytic astrocytoma. Cell Mol. Life Sci. 2012, 69, 1799–1811. [Google Scholar] [CrossRef] [PubMed]
- Ryall, S.; Zapotocky, M.; Fukuoka, K.; Nobre, L.; Stucklin, A.G.; Bennett, J.; Siddaway, R.; Li, C.; Pajovic, S.; Arnoldo, A.; et al. Integrated Molecular and Clinical Analysis of 1000 Pediatric Low-Grade Gliomas. Cancer Cell 2020, 37, 569–583.e5. [Google Scholar] [CrossRef]
- Lassaletta, A.; Zapotocky, M.; Mistry, M.; Ramaswamy, V.; Honnorat, M.; Krishnatry, R.; Stucklin, A.G.; Zhukova, N.; Arnoldo, A.; Ryall, S.; et al. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2017, 35, 2934–2941. [Google Scholar] [CrossRef]
- Bouffet, E.; Hansford, J.R.; Garre, M.L.; Hara, J.; Plant-Fox, A.; Aerts, I.; Locatelli, F.; van der Lugt, J.; Papusha, L.; Sahm, F.; et al. Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations. N. Engl. J. Med. 2023, 389, 1108–1120. [Google Scholar] [CrossRef]
- Hargrave, D.R.; Terashima, K.; Hara, J.; Kordes, U.R.; Upadhyaya, S.A.; Sahm, F.; Bouffet, E.; Packer, R.J.; Witt, O.; Sandalic, L.; et al. Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600-Mutant Pediatric High-Grade Glioma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2023, 41, 5174–5183. [Google Scholar] [CrossRef] [PubMed]
- Kaley, T.; Touat, M.; Subbiah, V.; Hollebecque, A.; Rodon, J.; Lockhart, A.C.; Keedy, V.; Bielle, F.; Hofheinz, R.-D.; Joly, F.; et al. BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study. J. Clin. Oncol. 2018, 36, 3477–3484. [Google Scholar] [CrossRef] [PubMed]
- Wen, P.Y.; Stein, A.; van den Bent, M.; De Greve, J.; Wick, A.; de Vos, F.; von Bubnoff, N.; van Linde, M.E.; Lai, A.; Prager, G.W.; et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): A multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol. 2022, 23, 53–64. [Google Scholar] [CrossRef] [PubMed]
- Arbour, G.; Ellezam, B.; Weil, A.G.; Cayrol, R.; Vanan, M.I.; Coltin, H.; Larouche, V.; Erker, C.; Jabado, N.; Perreault, S. Upfront BRAF/MEK inhibitors for treatment of high-grade glioma: A case report and review of the literature. Neurooncol. Adv. 2022, 4, vdac174. [Google Scholar] [CrossRef] [PubMed]
- Brown, N.F.; Carter, T.; Kitchen, N.; Mulholland, P. Dabrafenib and trametinib in BRAFV600E mutated glioma. CNS Oncol. 2017, 6, 291–296. [Google Scholar] [CrossRef] [PubMed]
- Sturm, D.; Pfister, S.M.; Jones, D.T.W. Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2017, 35, 2370–2377. [Google Scholar] [CrossRef] [PubMed]
- Long, G.V.; Stroyakovskiy, D.; Gogas, H.; Levchenko, E.; de Braud, F.; Larkin, J.; Garbe, C.; Jouary, T.; Hauschild, A.; Grob, J.J.; et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 2014, 371, 1877–1888. [Google Scholar] [CrossRef] [PubMed]
- Long, G.V.; Stroyakovskiy, D.; Gogas, H.; Levchenko, E.; de Braud, F.; Larkin, J.; Garbe, C.; Jouary, T.; Hauschild, A.; Grob, J.-J.; et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015, 386, 444–451. [Google Scholar] [CrossRef] [PubMed]
- Hargrave, D.R.; Terashima, K.; Hara, J.; Kordes, U.R.; Upadhyaya, S.A.; Sahm, F.; Bouffet, E.; Packer, R.J.; Witt, O.; Sandalic, L.; et al. Dabrafenib + trametinib (dab + tram) in relapsed/refractory (r/r) BRAF V600–mutant pediatric high-grade glioma (pHGG): Primary analysis of a phase II trial. J. Clin. Oncol. 2022, 40 (Suppl. S16), 2009. [Google Scholar] [CrossRef]
- Bautista, F.; Paci, A.; Minard-Colin, V.; Dufour, C.; Grill, J.; Lacroix, L.; Varlet, P.; Valteau-Couanet, D.; Geoerger, B. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. Pediatr. Blood Cancer 2014, 61, 1101–1103. [Google Scholar] [CrossRef]
- Lee, E.Q.; Ruland, S.; LeBoeuf, N.R.; Wen, P.Y.; Santagata, S. Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma with Vemurafenib Monotherapy. J. Clin. Oncol. 2016, 34, e87–e89. [Google Scholar] [CrossRef]
- Skrypek, M.; Foreman, N.; Guillaume, D.; Moertel, C. Pilomyxoid astrocytoma treated successfully with vemurafenib. Pediatr. Blood Cancer. 2014, 61, 2099–2100. [Google Scholar] [CrossRef]
- Lehmann, R.; Rayner, B.S.; Ziegler, D.S. Resistance mechanisms in BRAF(V600E) paediatric high-grade glioma and current therapeutic approaches. Front. Oncol. 2022, 12, 1031378. [Google Scholar] [CrossRef]
- van Tilburg, C.M.; Kilburn, L.B.; Perreault, S.; Schmidt, R.; Azizi, A.A.; Cruz-Martínez, O.; Zápotocký, M.; Scheinemann, K.; Meeteren, A.Y.N.S.-V.; Sehested, A.; et al. LOGGIC/FIREFLY-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration. BMC Cancer 2024, 24, 147. [Google Scholar] [CrossRef]
- Kilburn, L.B.; Khuong-Quang, D.A.; Hansford, J.R.; Landi, D.; van der Lugt, J.; Leary, S.E.S.; Driever, P.H.; Bailey, S.; Perreault, S.; McCowage, G.; et al. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: The phase 2 FIREFLY-1 trial. Nat. Med. 2024, 30, 207–217. [Google Scholar] [CrossRef]
- De La Fuente, M.I.; Rodon Ahnert, J.; Yaeger, R.; Tsai, F.Y.-C.; Janku, F.; Butowski, N.A.; Allen, C.E.; Ammakkanavar, N.R.; Taylor, J.W.; Michelson, G.; et al. Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study. Am. Soc. Clin. Oncol. 2023, 41, 3006. [Google Scholar] [CrossRef]
- Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.B.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987–996. [Google Scholar] [CrossRef] [PubMed]
- Rosenberg, T.; Yeo, K.K.; Mauguen, A.; Alexandrescu, S.; Prabhu, S.P.; Tsai, J.W.; Malinowski, S.; Joshirao, M.; Parikh, K.; Sait, S.F.; et al. Upfront Molecular Targeted Therapy for the Treatment of BRAF-Mutant Pediatric High-Grade Glioma. Neuro Oncol. 2022, 24, 1964–1975. [Google Scholar] [CrossRef] [PubMed]
- Anker, C.J.; Grossmann, K.F.; Atkins, M.B.; Suneja, G.; Tarhini, A.A.; Kirkwood, J.M. Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). Int. J. Radiat. Oncol. Biol. Phys. 2016, 95, 632–646. [Google Scholar] [CrossRef]
- Wang, W.; Smith, J.L.; Carlino, M.S.; Burmeister, B.; Pinkham, M.B.; Fogarty, G.B.; Christie, D.R.H.; Estall, V.; Shackleton, M.; Clements, A.; et al. Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma. Clin. Transl. Radiat. Oncol. 2021, 30, 95–99. [Google Scholar] [CrossRef]
- Bergeron Gravel, S.; Bouffet, E.; Tabori, U.; Hawkins, C.; Tsang, D.S. Re-irradiation with concurrent BRAF and MEK inhibitor therapy. Pediatr. Blood Cancer 2021, 68, e28838. [Google Scholar] [CrossRef] [PubMed]
- Nobre, L.; Zapotocky, M.; Ramaswamy, V.; Ryall, S.; Bennett, J.; Alderete, D.; Guill, J.B.; Baroni, L.; Bartels, U.; Bavle, A.; et al. Outcomes of BRAF V600E Pediatric Gliomas Treated with Targeted BRAF Inhibition. JCO Precis. Oncol. 2020, 4, 561–571. [Google Scholar] [CrossRef] [PubMed]
- Laflamme, P.; Kondyli, M.; Aljared, T.; Miconiatis, S.; Saint-Martin, C.; Farmer, J.P.; Dudley, R.W.; Sébastien, P.; Nada, J.; Valérie, L. Correction to: Efficacy of Dabrafenib for three children with brainstem BRAF(V600E) positive ganglioglioma. J. Neurooncol. 2019, 145, 595. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Erker, C.; Vanan, M.I.; Larouche, V.; Nobre, L.; Cacciotti, C.; Vairy, S.; Zelcer, S.; Fleming, A.; Bouffet, E.; Jabado, N.; et al. Canadian Consensus for Treatment of BRAF V600E Mutated Pediatric and AYA Gliomas. Curr. Oncol. 2024, 31, 4022-4029. https://doi.org/10.3390/curroncol31070299
Erker C, Vanan MI, Larouche V, Nobre L, Cacciotti C, Vairy S, Zelcer S, Fleming A, Bouffet E, Jabado N, et al. Canadian Consensus for Treatment of BRAF V600E Mutated Pediatric and AYA Gliomas. Current Oncology. 2024; 31(7):4022-4029. https://doi.org/10.3390/curroncol31070299
Chicago/Turabian StyleErker, Craig, Magimairajan Issai Vanan, Valérie Larouche, Liana Nobre, Chantel Cacciotti, Stéphanie Vairy, Shayna Zelcer, Adam Fleming, Eric Bouffet, Nada Jabado, and et al. 2024. "Canadian Consensus for Treatment of BRAF V600E Mutated Pediatric and AYA Gliomas" Current Oncology 31, no. 7: 4022-4029. https://doi.org/10.3390/curroncol31070299